INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, published by DUSTRI-VERLAG DR KARL FEISTLE in Germany, is a vital scholarly platform dedicated to advancing the field of pharmacology through rigorous research and innovative therapeutic strategies. Established in 1994, this journal has maintained its relevance in the evolving landscape of clinical pharmacology, achieving a Q3 rank in both general and medical pharmacology categories as of 2023. With an ISSN of 0946-1965, it is positioned as an essential resource for researchers, healthcare professionals, and students seeking to enhance their understanding of drug therapy and pharmacological applications. Though it currently does not offer open access, its comprehensive scope covers a wide array of topics within pharmacology, promising to contribute significantly to scientific discussions and knowledge dissemination from 1994 to 2024. Whether you are looking for the latest studies or historical insights, the journal remains a fixture for anyone invested in the pharmacological sciences.

International Journal of Pharmaceutical Investigation, published by INPHARM ASSOC, PHCOG NET, is a premier platform dedicated to advancing the field of pharmaceutical sciences. With the ISSN 2230-973X and E-ISSN 2230-9713, this journal serves as a vital resource for researchers, professionals, and students focused on drug development, formulation, and efficacy. By fostering a rich discourse on innovative pharmaceutical practices and research breakthroughs, the journal plays a critical role in enhancing global health outcomes through groundbreaking scholarly work. The absence of open access allows for selective dissemination of high-quality content, promoting rigorous peer-review processes that uphold academic integrity. Featuring articles that span a diverse range of topics within pharmaceutical sciences, the International Journal of Pharmaceutical Investigation is committed to supporting the ongoing evolution of this dynamic field, making it an essential read for anyone engaged in pharmaceutical research and development.

PHARMACOTHERAPY, an esteemed journal published by WILEY, stands as a pivotal resource within the field of medical pharmacology. With its ISSN 0277-0008 and E-ISSN 1875-9114, this journal has been at the forefront of pharmacological research since its inception in 1981. Renowned for its rigorous peer-review process and impactful contributions, it currently holds a prestigious Q1 quartile ranking in the pharmacology category, underscoring its significance as a leading publication in the field. It ranks #40 out of 272 journals in Scopus, placing it in the top 15% percentile of its category. While not an open-access publication, PHARMACOTHERAPY remains committed to advancing knowledge and understanding in pharmacological sciences, making it an indispensable resource for researchers, healthcare professionals, and students dedicated to improving therapeutic outcomes and drug utilization. Based in the United States, at 111 River St, Hoboken, NJ, the journal is poised to continue its impact through to 2024 and beyond, welcoming contributions that further the discourse in pharmacotherapy.

Clinical Pharmacology in Drug Development, published by WILEY, is a distinguished journal dedicated to advancing the field of pharmaceutical science and drug development. With a strong commitment to disseminating cutting-edge research, this journal serves as a crucial platform for professionals, researchers, and students aiming to enhance their understanding of pharmacological principles and innovations in medical therapeutics. Since its inception in 2012, the journal has consistently maintained a noteworthy presence in the academic community, currently achieving a Q2 ranking in both Pharmaceutical Science and Medical Pharmacology categories as of 2023. Although the journal operates under a subscription model, it is highly regarded for its rigorous peer-reviewed publications, offering insights into drug efficacy, safety, and regulatory challenges. Positioned at the intersection of clinical practices and pharmaceutical advancements, Clinical Pharmacology in Drug Development plays an essential role in bridging the gap between scientific research and real-world application, ensuring that the latest therapeutic strategies are optimized for patient care.

The JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, published by the American Society for Pharmacology and Experimental Therapeutics, stands as a pivotal platform in the fields of pharmacology and molecular medicine. With an impressive convergence of knowledge from 1945 to 2024, this esteemed journal is recognized for its rigorous peer-reviewed research, contributing significantly to our understanding of drug action and therapeutic interventions. It holds a commendable position in the Q2 quartile in both Molecular Medicine and Pharmacology, emphasizing its relevance and impact within the contemporary scientific landscape, as evidenced by its Scopus ranking that places it amongst the leading journals in its category. Aimed at researchers, professionals, and students, the journal not only fosters a deeper insight into toxicology, pharmacodynamics, and therapeutic strategies but also encourages innovation through its comprehensive access to groundbreaking experimental methodologies. The journal continues to foster discourse and disseminate research that shapes the future of pharmacological science.

Frontiers in Pharmacology, published by FRONTIERS MEDIA SA, stands as a leading open-access journal dedicated to advancing the field of pharmacology since its inception in 2010. With its ISSN 1663-9812, the journal is based in Switzerland and maintains a vital role in disseminating innovative research findings that span various disciplines within pharmacology, including pharmacokinetics, toxicology, and pharmacogenetics. In 2023, Frontiers in Pharmacology has achieved an impressive standing within the scientific community, being ranked in the Q1 category for both general and medical pharmacology, highlighting its critical contribution to the field with a Scopus ranking of #41 out of 272 in medical pharmacology and #76 out of 313 in pharmacology, toxicology, and pharmaceutics, placing it in the 75th and 85th percentiles, respectively. Researchers and practitioners benefit from its open-access model, which ensures widespread accessibility to groundbreaking research, fostering collaboration and innovation across the pharmaceutical sciences. With its commitment to excellence, Frontiers in Pharmacology serves as an essential resource for those looking to explore and contribute to the latest advancements in pharmacological research.

BIOLOGICAL & PHARMACEUTICAL BULLETIN, published by the PHARMACEUTICAL SOC JAPAN, is a prominent peer-reviewed journal that serves the fields of medicine, pharmaceutical science, and pharmacology. With an ISSN of 0918-6158 and an E-ISSN of 1347-5215, this publication has been crucial in disseminating innovative research since its inception in 1993, and it continues to contribute significantly to the body of knowledge as it converges towards 2024. Despite being classified as a non-open access journal, it maintains a respectable Q3 ranking in Medicine (miscellaneous) and Q2 in Pharmaceutical Science, highlighting its critical role in advancing scientific discourse in these areas. With Scopus rankings placing it in the 51st percentile for Pharmaceutical Science and 38th percentile for Pharmacology, BIOLOGICAL & PHARMACEUTICAL BULLETIN is an essential resource for researchers, professionals, and students looking to stay abreast of cutting-edge developments and trends in biomedicine and drug development.

British Journal of Pharmacology is a premier, peer-reviewed journal published by Wiley, specializing in the dynamic field of pharmacology. With a robust impact factor, this journal ranks in the top quartile (Q1) for pharmacology according to the 2023 category rankings, emphasizing its significance and reputation among the global scientific community. As an essential resource for researchers, professionals, and students alike, the journal provides a platform for innovative research spanning foundational studies to clinical applications in pharmacology, toxicology, and pharmaceutics. Since its inception in 1966, the journal has consistently contributed to the advancement of pharmacological science, fostering a deeper understanding of drug action mechanisms and therapeutic advancements. Although primarily subscription-based, the British Journal of Pharmacology is committed to disseminating high-quality research that shapes the future of the field.

Clinical Pharmacology-Advances and Applications is a premier open access journal published by DOVE MEDICAL PRESS LTD, based in New Zealand. Since its establishment in 2009, the journal has been dedicated to advancing the field of pharmacology by disseminating innovative research and applications related to medication therapy and patient outcomes. With its notable impact factor and current ranking within the top percentile of pharmacology journals, it provides an invaluable platform for researchers, healthcare professionals, and students to share knowledge and foster collaboration. The journal's content spans a wide range of topics, ensuring coverage of both fundamental and emerging areas in medical pharmacology. As of 2023, it holds a strong position in the Q2 quartile, underscoring its relevance and influence within the scientific community. Authors and readers alike benefit from its open access model, which ensures that critical findings are widely accessible, thereby enhancing the pace of discovery and application in clinical settings.

Current Drug Safety is a distinguished peer-reviewed journal published by Bentham Science Publishers, focusing on the critical intersection of pharmacology and toxicology. With an ISSN of 1574-8863 and an E-ISSN of 2212-3911, this journal serves as a platform for the latest research and advances in drug safety, highlighting the importance of pharmacological assessments and toxicity evaluations in therapeutic development and public health. Reaching a broad international audience from its base in the United Arab Emirates, Current Drug Safety offers an invaluable resource for researchers, professionals, and students interested in the dynamic fields of drug research and safety management. Despite a current Q3 categorization in multiple pharmacology and toxicology quartiles for 2023, the journal continues to strive for excellence in the scholarly community, reflecting its commitment to disseminating high-quality research. While not operating under an open access model, articles can be accessed through institutional subscriptions and other platforms, ensuring valuable insights into drug safety are available to those who need it most.